The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The European Mediscience Awards is an esteemed event that celebrates achievement and success in the UK and European healthcare, biotech, pharmaceutical, and life sciences sectors. Here are some key details about the awards:
Purpose: The awards showcase outstanding accomplishments within the mediscience industry.
Annual Gathering: It is the largest annual gathering of private and publicly quoted healthcare, biotech, and life sciences companies in Europe.
Attendance: Each year, over 500 quoted and private UK and European life sciences companies, along with their corporate advisers, analysts, fund managers, commentators, and peers, attend the event.
22nd Year: The European Mediscience Awards has been held every year since its inception in 2002 (with the exception of 2020 due to COVID-19, when a successful digital campaign was held instead).
Event Date: The European Mediscience Awards 2024 will take place on Thursday, June 13 at the Hotel InterContinental, London, W1.
Categories: The awards cover achievements during the period from April 1, 2023, to March 31, 2024.
Recognition: Winners are announced at the gala dinner, making it a prestigious recognition for those working in the mediscience sector.
Patients are currently being dosed. SDMC were due to review C1 towards end of April, of course that is not within Avacta's gift to dictate, they hand over the results and they are reviewed. Hoping then for an update in the coming weeks.
LR19129 still listed in the LG Chem pipeline
https://innovation.lgchem.com/ResearchDevelopment/Pipeline.do
https://www.lgchem.com/company/company-information/business-domain/biology?lang=en_US
There you go again 😂 Why would you voluntarily dredge up your own example of spouting horsesh*t? Now back it up with something factual. Have you spoken to CC about this, or are you in fact just making it up?
Good to see someone taking some action:
https://twitter.com/pau79021/status/1786407762643046491/photo/1
Founded in Q3 of 2005, GSA Capital Partners is a London-based quantitative hedge fund manager. It focuses on systematic trading across liquid equity, futures, and foreign exchange markets globally. The firm was formed in 2001 as the global statistical arbitrage group of DB Advisors, a proprietary trading unit of Deutsche Bank. It spun out of the bank in 2005 to create an independent hedge fund management company.
What a bunch of c***s.
Don't agree with that gmcc. What you are describing is just an accountant preparing the accounts. A CFO is supposed to be the money person who understands the financial requirements of the company, has links with the investment community and steers them through fundraises.
From a couple of websites:
Rolls of a CFO:
"1) growing the company faster, 2) improving profitability, 3) improve cash flow, 4) obtain increased leverage from banks, and 5) provide leadership and direction throughout the company"
"
What does a CFO do in a company?
CFOs make sensible and successful financial decisions that work in the business’s favor to increase revenue and profitability.
The role of the CFO is varied and can include:
Advising on financial best-practice
Guiding on policy and compliance
Securing investment
Getting the business ready for IPO (Initial Public Offering)
Matching the finance team’s talent strategy with the needs of the business
Deciding on financial systems, processes, and technology "
Our CFO failed in these respects.
Https://x.com/cumulus51896691/status/1786072627511001481?s=46&t=A543JZMlg2Q8YTCvlVat_w
“However, despite recent successes, the clinical development of ADCs has been associated with a high failure rate, as off-site toxicity remains problematic, limiting tolerable ADC doses to levels below those required for substantial anti-cancer efficacy [7,8,9,10]. Even for the ADCs that have gained FDA approval, a significant fraction of treated patients require supportive treatment to reduce the severity of ADC-associated toxicities, and many patients require dose reduction, treatment delays, or treatment discontinuation”
let's just break this down shall we. you said:
"the exceptional clinical results are no more exceptional than that extrapolated from the mouse trials."
what's the point in this comment exactly? this is like saying messi's exceptional ability in the second half of the match was no more exceptional than his ability in the second half. why the **** would anyone say that? but anyway, i think i understand what you are saying is that the results in both the mouse trials and the p1a phase so far are exceptional. we can agree on that despite the bizarre turn of phrase.
you said:
"chris made a point that the amount of dox in the tumour was not directly proportional to fap present so why is there such a range of tumour shrinkage or in some cases continuing growth?"
you also said:
"look at the f*cking slide"
that's great advice, which you seem to have ignored yourself. multiple times ice has told you the reason, multiple times you keep on ignoring the reply. watch the ******* presentation. keep watching it until it sinks in.
just so you are clear:
what the data tells us in that slide is that precision is working "its magic" in high and mid fap tumours and is resulting in dox, or indeed whatever warhead you choose to attach, concentrating in the tumour. cc went on to say that in the patients treated so far, the responses correlated with tumours that were known to respond to dox, and it just so happened that these were also the ones high in fap.
the overwhelmingly positive takeaway from this is that we are likely to see ava6000 being efficacious in dox sensitive tumours that are both high and mid fap!